Biogen’s MS Drug Meets Goals in Second Trial

Biogen Idec’s oral multiple sclerosis drug, BG-12, outperformed Teva’s Copaxone in a recent Phase III study for multiple sclerosis in 2,600 patients, reducing relapse rates to 44% and 51% for groups taking a 240 mg pill either twice or three times a day over two years, respectively. With its MS program on-track, and recognizing that the anti-inflammatory effects of BG-12 may extend to other neurodegenerative diseases, Biogen plans to explore the therapeutic potential of BG-12 for ALS in preclinical models.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail